Good Life Advisors LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 58.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 4,868 shares of the biopharmaceutical company’s stock after selling 6,748 shares during the period. Good Life Advisors LLC’s holdings in Gilead Sciences were worth $450,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of the stock. HHM Wealth Advisors LLC boosted its holdings in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Gilead Sciences in the third quarter worth about $25,000. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences during the 4th quarter worth about $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at about $29,000. Finally, Valued Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.
Gilead Sciences Price Performance
Shares of GILD opened at $110.03 on Friday. The firm has a 50-day simple moving average of $95.05 and a two-hundred day simple moving average of $88.38. The stock has a market cap of $137.13 billion, a PE ratio of 297.38, a P/E/G ratio of 0.88 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $110.11. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.
Gilead Sciences Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a dividend of $0.79 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.87%. Gilead Sciences’s dividend payout ratio is presently 832.43%.
Analyst Ratings Changes
GILD has been the topic of several research analyst reports. BMO Capital Markets raised their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Morgan Stanley boosted their price target on shares of Gilead Sciences from $113.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $102.08.
View Our Latest Stock Report on GILD
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total value of $260,225.00. Following the completion of the transaction, the chief financial officer now owns 169,061 shares of the company’s stock, valued at $17,597,559.49. This trade represents a 1.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 713,000 shares of company stock valued at $67,945,181 in the last three months. 0.16% of the stock is owned by corporate insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
- Five stocks we like better than Gilead Sciences
- Earnings Per Share Calculator: How to Calculate EPS
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- 10 Best Airline Stocks to Buy
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.